| www.bioportfolio.com |
http://www.bioportfolio.co.uk/bulletin_54.htm
September
21st 2004 |
|
|
Lead Sponsor:
Advanced
Asset Services, Inc. Auctioneers
|
|
MILLENNIUM
PHARMACEUTICALS, INC.
Major 2 DAY Webcast LAB Auction
Equipment Surplus to on-going operations, Over
1500 Lots! ABI, HP, Molecular Devices, Tecan,
Beckman, New Brunswick & Much Much, More... Bid On-Location or Bid on
the Web at our website!
| Auction
Date/Time: |
September,
29th & 30th
10AM (EDT) |
| Inspection Date/Time: |
September,
28th
9AM-4PM (EDT) |
| Location: |
640
Memorial Drive, Cambridge, MA |
| Details: |
www.advancedlink.com |
|
|
In this Week's issue:
- NEWS - BioNews
Headlines and content -
over 400
life science industry news stories per day [more]
-
BPS Announces -
Biomanufacturing Database Update [more]
- CAREERS - 100's of
jobs - 3:1 deal for recruiters [more]
- BIOPHEX 2004 - http://www.biophex.com
San Francisco Sept
28th to 30th 2004
- REPORTS - 20 new reports by Jain
PharmaBiotech [more]
+ Biotechnology Management
Practices [more]
- OPINIONS -
TherapeuticAdvances
selected items on research
and drug development
[more]
|
|
BPS Announces -
Biomanufacturing Database Update
|
|
|
BioPharm Services (BPS)
databases. Sign up today for:
Biomanufacturers
Capacity Database - Searchable database of manufacturers, CMOs
& fill finish companies identifying; sites, manufacturing
capabilities, experience & capacities
UPDATED: Now
includes fully searchable information on vaccine manufacturers.
http://www.biopharmservices.com/redirect.aspx?click=BioPortfolioAUG2004&redirect=mdb_Home
|
|
NEWS - BioNews Headlines
and content
|
|
Every 30 minutes BioPortfolio
updates the BioNews service with the latest news items collated from
thousands of published sources. In addition we carry full text press
releases for over 300 which are added to the site daily at 12:30 GMT.
To full evaluate the
service and to take advantage of our email alert service visit:
BioWatch BioNews Tracking:
http://www.bioportfolio.com/news_tracking/index.htm
To search go to:
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?FILE=search&SAVEDB=news
|
|
CAREERS - Job Seekers and
Employers
|
|
Job Seekers
Careers
Home Page
|
|
Employers
The BioJobNetwork can help you get your Fall recruiting on the fast track.
Reach candidates through our network of thirteen career centers catering
to the biosciences professional. Submit your listings to display on all
thirteen career centers and broaden your visibility and reach.
Login
your BioPortfolio employer account now.
About the BioJobNetwork Posting
Package:
- Use Coupon RP77UK5 to
post 3 jobs for $125. Enter coupon at login.
- Each posting runs for 60
days.
- Coupon is good through
September 30th.
- Reach 13 industry sites with
a single posting: BiotechCareerCenter, BioJobNet, BioPortfolio,
BioProcessing International, Drug Delivery Technology, EyeforPharma,
International Association of Nanotechnology, MolBiol, NanoBiotech
News, Society For Biomaterials, Society for Bioprocessing
Professionals, and ThePharmaNetwork. More partners soon to be
announced!
http://www.biojobnetwork.net/bioportfolio/?a=employer
|
|
|
Headline Sponsor
|
|
BIOPHEX delivers a unique perspective on
the strategic and managerial issues that affect everyone in post-discovery
development and manufacturing. The conference, produced by Genetic
Engineering News, is targeted to help top-level biopharmaceutical
professionals successfully transition their drug from post-discovery to
market. For more information open:
http://www.biophex.com
San Francisco Sept
28th to 30th 2004
|
|
|
Reports.
|
|
|
|
Biotechnology
Management Practices
Mardis Aibel have performed a unique study:
> the first objective look at the role of management in the US
Biotechnology Industry
> views from within, from biotech industry specialists and the
investment community
> identifying the practices that work and those that don’t
highlighting the unique management challenges biotech industry faces
Methodology
> Interviewed over 200 executives from 56 North American Biotech
companies (late 2003)
> Involved CEOs, COOs, CFOs, CTOs and senior HR executives
> Companies ranged from start-ups to fully integrated
biopharmaceuticals
Purchase online: $995.00
http://www.bioportfolio.com/cgi-bin/acatalog/progenta.html
|
|
Jain
PharmaBiotech Report
|
|
To view
descriptions and buy online - click
here! or select the title!
Molecular
Diagnostics - Technologies, Markets and Companies
This report describes and evaluates the molecular diagnostics
technologies that will play an important role in practice of
medicine, public health, pharmaceutical industry, forensics and
biological warfare in the 21st century. This includes several
polymerase chain reaction (PCR)-based technologies, fluorescent in
situ hybridization (FISH), peptide nucleic acids (PNA),
electrochemical detection of DNA, biochips, nanotechnology and
proteomic technologies.
|
Cell
Therapy - Technologies, Markets and Companies
This report describes and evaluates cell therapy technologies and
methods, which have already started to play an important role in
the practice of medicine. Hematopoietic stem cell transplantation
is replacing the old fashioned bone marrow transplants. Cell
therapy is bound to become a part of medical practice.
|
Proteomics
- Technologies, Markets and Companies
This report describes and evaluates the proteomic technologies
that will play an important role in drug discovery, molecular
diagnostics and practice of medicine in the post-genomic era - the
first decade of the 21st century. Most commonly used technologies
are 2-D gel electrophoresis for protein separation and analysis of
proteins by mass spectrometry. Microanalytical protein
characterization with multidimentional liquid chromatography/mass
spectrometry improves the throughput and reliability of peptide
mapping. Matrix-Assisted Laser Desorption Mass Spectrometry (MALDI-MS)
has become a widely used method for determination of biomolecules
including peptides, proteins. Functional proteomics technologies
include yeast two-hybrid system for studying protein- protein
interactions.
|
Neuroprotection
- Drugs, Markets and Companies
This report describes the role of neuroprotection in acute
disorders such as stroke and injuries of the nervous system as
well as in chronic diseases such as neurodegenerative disorders
because many of the underlying mechanisms of damage to neural
tissues are similar in all these conditions and several products
are used in more than one disorder. Over 300 products have been
investigated for neuroprotective effects including those from the
categories of free radical scavengers, anti-excitotoxic agents,
apoptosis (programmed cell death) inhibitors, anti-inflammatory
agents, neurotrophic factors, metal ion chelators, ion channel
modulators and gene therapy. Some of the agents are old
established pharmaceuticals whereas others are new biotechnology
products.
|
Transdermal
Drug Delivery - Technologies, Markets, and Companies
This report deals with transdermal drug delivery - an approach
used to deliver drugs through the skin for therapeutic use as an
alternative to oral,intravascular, subcutaneous and transmucosal
routes. Various transdermal drug delivery technologies are
described including the use of suitable formulations, carriers and
penetration enhancers. The most commonly used transdermal system
is the skin patch using various types of technologies. Transdermal
technologies may be applied for several categories of
pharmaceuticals used for the treatment of disorders of the skin or
for systemic effect to treat diseases of other organs. There are
eight categories of transdermal products and applications include
hormone replacement therapy, management of pain, angina pectoris,
smoking cessation and neurological disorders such as Parkinson's
disease. The value of market for transdermal delivery is $8
billion in the year 2002 and is expected to increase to $16.3
billion in the year 2007.
|
Animal
Biotechnology - Technologies, Markets and Companies
This report describes and evaluates animal biotechnology and its
application in veterinary medicine and pharmaceuticals as well as
improvement in food production. Knowledge of animal genetics is
important in the application of biotechnology to manage genetic
disorders and improve animal breeding. Genomics, proteomics and
bioinformatics are also being applied to animal biotechnology.
|
Pain
Therapeutics - Drugs, Markets and Companies
This report describes the latest concepts of pathomechanisms of
pain as a basis for management and development of new
pharmacotherapies for pain. Major segments of the pain market are
arthritis, neuropathic pain and cancer pain. Because pain is a
subjective sensation, it is difficult to evaluate objectively in
clinical trials. Various tools for pain measurement are described,
including brain imaging.
|
Personalized
Medicine - scientific & commercial aspects
The aim of personalized medicine or individualized treatment is to
match the right drug to the right patient and, in some cases, even
to design the appropriate treatment for a patient according to
his/her genotype. This report describes the latest concepts of
development of personalized medicine based on pharmacogenomics,
pharmacogenetics and pharmacoproteomics. Basic technologies of
molecular diagnostics play an important role, particularly those
for single nucleotide polymorphism (SNP) genotyping. Diagnosis is
integrated with therapy for selection of the treatment as well for
monitoring the results. Biochip/microarray technologies are also
important and finally bioinformatics is needed to analyze the
immense amount of data generated by various technologies.
|
Nitric
Oxide - Therapeutics, Markets and Companies
This report describes the latest concepts of the role of nitric
oxide (NO) in health and disease as a basis for therapeutics and
development of new drugs. Major segments of the market for nitric
oxide-based drugs are described as well as the companies involved
in developing them.
|
Alzheimer
disease - new drugs, markets and companies
Alzheimer's disease remains a challenge in management. With nearly
8 million sufferers from this condition in the seven major markets
of the world and anticipated increases in the future. Considerable
research is in progress to understand the pathomechanism of the
disease and find a cure. The only drugs approved currently are
acetylcholinesterase inhibitors but they do not correct the basic
pathology of the disease, beta amyloid deposits and
neurofibrillary tangles. Several new approaches emphasize
neuroprotection as well.
|
Drug
Delivery in Cancer - technologies, markets and companies
Drug delivery remains a challenge in management of cancer.
Approximately 11 million persons are estimated to be diagnosed
with cancer worldwide in 2003 and considerable research is in
progress for drug discovery for cancer. Cancer drug delivery is no
longer simply wrapping up cancer drugs in a new formulations for
different routes of delivery. The focus is on targeted cancer
therapy. The newer approaches to cancer treatment not only
supplement the conventional chemotherapy and radiotherapy but also
prevent damage to normal tissues and prevent drug resistance.
|
RNAi
- technologies, markets and companies
RNA interference (RNAi) or gene silencing involves the use of
double stranded RNA (dsRNA). Once inside the cell, this material
is processed into short 21-23 nucleotide RNAs termed siRNAs that
are used in a sequence-specific manner to recognize and destroy
complementary RNA. The report compares RNAi with other antisense
approaches using oligonucleotides, aptamers, ribozymes, peptide
nucleic acid and locked nucleic acid.
|
Gene
Therapy - technologies, markets and companies
Gene therapy can be broadly defined as the transfer of defined
genetic material to specific target cells of a patient for the
ultimate purpose of preventing or altering a particular disease
state. Genes and DNA are now being introduced without the use of
vectors and various techniques are being used to modify the
function of genes in vivo without gene transfer. If one adds to
this the cell therapy particularly with use of genetically
modified cells, the scope of gene therapy becomes much broader.
Gene therapy can now combined with antisense techniques such as
RNA interference (RNAi), further increasing the therapeutic
applications. This report takes broad overview of gene therapy and
is the most up-to-date presentation from the author on this topic
built-up from a series of gene therapy report written by him
during the past decade including a textbook of gene therapy and a
book on gene therapy companies. This report describes the setbacks
of gene therapy and renewed interest in the topic
|
Nanobiotechnologies-
applications, markets and companies
Nanotechnology is the creation and utilization of materials,
devices, and systems through the control of matter on the
nanometer-length scale (a nanometer is one billionth of a meter.
Nanobiotechnology, an integration of physical sciences, molecular
engineering, biology, chemistry and biotechnology holds
considerable promise of advances in pharmaceuticals and
healthcare. The report starts with an introduction to various
techniques and materials that are relevant to nanobiotechnology.
It includes some of the physical forms of energy such as
nanolasers. Some of the technologies are scaling down such as
microfluidics to nanofluidic biochips and others are constructions
from bottom up. Application in life sciences research,
particularly at the cell level sets the stage for role of
nanobiotechnology in healthcare in subsequent chapters.
|
Drug
Delivery in Central Nervous System Disorders - technologies,
markets and companies
The delivery of drugs to central nervous system (CNS) is a
challenge in the treatment of neurological disorders. Drugs may be
administered directly into the CNS or administered systematically
(e.g., by intravenous injection) for targeted action in the CNS.
The major challenge to CNS drug delivery is the blood-brain
barrier (BBB), which limits the access of drugs to the brain
substance. |
|
|
OPINIONS
|
|
From LeadDiscovery and
Datamonitor
|
|
LeadDiscovery
|
|
TherapeuticAdvances
is up-dated twice-monthly highlighting 100's of breaking research
projects selected to stimulate target discovery activity - click sections below:-
To view the
2002 Archive - click
here! - for the 2003 Archive - click
here!
Pharma
NewsBytes
features selected
press releases recently featured on DailyUpdates and offers the
reader a leisurely stroll through the past few weeks of activity from
within the pharmaceutical industry [more].
Sept 1 - 14 2004:
-
News on asthma
therapeutics presented at the European Respiratory Society [more]
-
Stroke
prevention - good and bad news [more]
-
News from the
European Association for the Study of Diabetes [more]
-
Long-awaited
FDA decisions on pain therapeutics [more]
|
|
Datamonitor
|
|
Omnitrope
deferral casts doubt over biogeneric development
Harsh
environment threatens antibacterial development
|
Contact
us:
Editorial and features: peter.barfoot@bioportfolio.com
Subscriber information:
To subscribe for
the BioPortfolio Bulletin in HTML, email:
bioportfolio-subscribe-request@peach.ease.lsoft.com
To unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com
WITH NO SUBJECT. The system will automatically remove
your email address from the list based on your email
address. If your email has changed please email peter.barfoot@bioportfolio.com
with a list of your email address and we will manually
unsubscribe for you. Thank you for your understanding.
©2004 BioPortfolio Limited
- http://www.bioportfolio.com and http://www.bioportfolio.co.uk
|
|
